Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2019—MedTest Dx introduced at the 2019 American Association for Clinical Chemistry annual scientific meeting an improved line of Clinitox Calibrators and Controls for confirmation testing. The product line aims to provide laboratories performing drugs of abuse testing a comprehensive and reliable calibration and controls solution with extended shelf life and simplified documentation.
August 2019—The U.S. Food and Drug Administration authorized marketing of a diagnostic test to detect Zika virus immunoglobulin antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA (InBios, Seattle) is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies, including the InBios test, had been authorized only for emergency use.
August 2019—NeuMoDx Molecular launched its CE-IVD assays for hepatitis B virus and hepatitis C virus. The company also launched CE-IVD assays for cytomegalovirus and Epstein-Barr virus.
August 2019—LGC Maine Standards released its Validate SP3 linearity and calibration verification kit for Roche Cobas and Beckman Coulter Immage analyzers. The kit, in a human serum matrix, evaluates α1-acid glycoprotein, antistreptolysin O, B2-microglobulin, and immunoglobulin E.
August 2019—Hamilton Company and Enable Biosciences announced a collaboration to provide fully automated processing of up to 96 liquid biopsy samples at one time using a novel ultra-sensitive and highly specific immunoassay in a hands-free workflow. The immunoassay, available for research applications in type 1 diabetes, Lyme disease, allergy, and HIV testing, is intended to support development of early-stage treatment interventions to improve patient health and quality of life with reduced disease-related complications.
August 2019—MDxHealth announced that a second clinical validation study demonstrating the performance of its liquid biopsy test SelectMDx for prostate cancer has been published in the Journal of Urology (Haese A, et al. 2019;202[2]:256–263).
August 2019—Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with olaparib (Lynparza, AstraZeneca) in the phase three POLO study. Results of the study were presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago.
August 2019—Loop Genomics has expanded its kits and services capabilities to provide researchers with ultra-high resolution microbiome sequencing solutions using long reads on Illumina sequencers. The four kits are a low biomass (e.g. human skin) phased V1–V9 full-length 16S kit with picogram input amounts and zero human DNA background, a phased 18S-ITS1-ITS2 long-read solution for ultra-high
August 2019—Thermo Fisher introduced its Invitrogen Collibri DNA Library Prep Kits for high-throughput Illumina systems. The kits contain a tracking dye to provide an in-process visual cue, which aims to improve workflow success.
August 2019—Motic Digital Pathology released the latest version of the FS-Live Telepathology Suite for remote pathology consultation and diagnosis. The updated software upgrades FS-Live to load up to six slides at a time, for individual live viewing and remote control.
